PRESERVE: A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer (clinicaltrials.gov) - Sep 17, 2026 - P2 | N=25 | Not yet recruiting | Sponsor: University of Utah
New P2 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer
|